Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial
Top Cited Papers
- 1 April 2020
- journal article
- research article
- Published by Elsevier in The Lancet Neurology
- Vol. 19 (4) , 298-306
Abstract
No abstract availableKeywords
Funding Information
- Kyoto University
- Fukushima University
- Ministry of Health, Labour and Welfare (H30/H31/R1-Nanchi-Ippan-043)
- Japan Agency for Medical Research and Development (JP17ek0109090)
This publication has 30 references indexed in Scilit:
- Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum DisordersJAMA Neurology, 2016
- Failure of Natalizumab to Prevent Relapses in Neuromyelitis OpticaArchives of Neurology, 2012
- Repeated Treatment With Rituximab Based on the Assessment of Peripheral Circulating Memory B Cells in Patients With Relapsing Neuromyelitis Optica Over 2 YearsArchives of Neurology, 2011
- Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximabNeurology, 2011
- IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrumNeurology, 2010
- Treatment of Neuromyelitis Optica With RituximabArchives of Neurology, 2008
- An open label study of the effects of rituximab in neuromyelitis opticaNeurology, 2005
- Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2004
- The clinical course of neuromyelitis optica (Devic’s syndrome)Neurology, 1999
- Rating neurologic impairment in multiple sclerosisNeurology, 1983